Collaboration between FESCA, SSoC and BI

in this section:

News →
Newsletter →
Events →
World Scleroderma Day →
Systemic Sclerosis World Congress →

Collaboration between FESCA, Scleroderma Society of Canada and Boehringer Ingelheim

In April, FESCA and the Scleroderma Society of Canada signed an agreement with Boehringer Ingelheim with the intention of working together to advance clinical research and improve awareness of systemic sclerosis (SSc) also known as scleroderma.

Called a Memorandum of Understanding, and written with the assistance and moderation of Eurordis, this agreement is not legally binding and is designed to be fully transparent to everyone. Its immediate goal is to include further patient expertise in the follow-through of a new ongoing trial called SENSCIS, which has been designed to understand if a drug approved for treatment of idiopathic lung fibrosis could also provide a benefit for patients with interstitial lung disease associated with SSc.